Diagnostics

Avant Technologies Signs Letter of Intent for a Business Combination

Avant Technologies, Inc. (OTCQB: AVAI) (“Avant” or the “Company”), announces that it has entered into a non-binding letter of intent (“LOI”) for a potential business combination with Ainnova Tech, Inc. (Ainnova). Ainnova, the Company’s joint venture partner, is a leading healthcare technology company focused on revolutionizing early disease detection using artificial intelligence (AI). Ainnova’s technology […]

Avant Technologies Signs Letter of Intent for a Business Combination Read More »

Sixth Street-Backed Caris Life Sciences Targets $5.3B Valuation in US IPO

Cancer diagnostic firm Caris Life Sciences said on Monday it is targeting a valuation of up to $5.3 billion in its U.S. initial public offering, as the market for new listings rebounds. Irving, Texas-based Caris, backed by investment firm Sixth Street, is seeking up to $423.5 million by offering 23.5 million shares priced between $16

Sixth Street-Backed Caris Life Sciences Targets $5.3B Valuation in US IPO Read More »

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256M

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announces it has been named the successful bidder in the bankruptcy auction for substantially all of the assets of 23andMe Holding Co., a leading human genetics and biotechnology company. Regeneron intends to acquire 23andMe’s Personal Genome Service® (PGS), Total Health and Research Services business lines, together with its Biobank and

Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256M Read More »

QIAGEN Enhances Leading Clinical Genomics Portfolio with Acquisition of Genoox AI-Powered Software

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announces it has signed a definitive agreement to acquire Genoox, a provider of AI-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests. The acquisition adds Franklin, Genoox’s flagship cloud-based community platform, to the QIAGEN Digital Insights (QDI) portfolio, strengthening QIAGEN’s leadership

QIAGEN Enhances Leading Clinical Genomics Portfolio with Acquisition of Genoox AI-Powered Software Read More »

Scroll to Top